Description of the Report

The radiation proctitis market is predicted to grow at a healthy rate of 7% between 2021 and 2031. Demand for acute radiation proctitis treatment is high, while over the coming years, the need for chronic radiation proctitis treatment is expected to increase significantly. Radiation proctitis treatment is grabbing eyeballs, with major healthcare providers and companies augmenting their R&D capacities to introduce highly advanced treatment approaches. Additionally, the rising hospitalization rate for major types of cancers is pushing the use of radiation therapy, which leads to the development of diseases like ulcerative colitis.

Manufacturers are mostly focusing on the need for chronic treatment for radiation proctitis in light of the high radiation doses administered to prostate and cervical cancer patients. The industry is promoting key strategies such as Hyperbaric Oxygen Therapy (HBOT) to tackle the growing issue and provide substantial advantages.

In its new report, consultant firm Fact. M.R. provides insights into the main factors driving demand for treatment for radiation proctitis. The study tracks sales worldwide in 20 markets that are growing rapidly and analyzes the impact COVID-19’s legislation has had on the field of healthcare generally as well as the demand for radiation proctitis treatments specifically.

Historical Trends vs. Future Growth Forecasts

With the worldwide increase in cancer incidence, patients are seeking high-quality treatment methods, including radiotherapy and chemotherapy. Numerous clinical studies were conducted earlier to prove the effectiveness of various treatments. In 2019 the market had surpassed US300 million dollars.

During the COVID-19 pandemic sweeping the world, the market saw significant advancement, specifically in regards to the increased accessibility of hyperbaric oxygen therapy (HBOT) in that it increases blood oxygen levels to reduce the possibility of inflammation in tissues and muscles. But, a slight blip was observed in the beginning due to the delay of the surgery elective.

Under Fact. Mrs projections, prospects are generally positive for 2021. Long-term prospects are also positive, with the projected CAGR of 7 percent for the next ten years and a market worth of close to US$750 million in 2031.

What is the reason for the rising Pelvic Cancer Burden driving demand for Radiation Proctitis Treatment?

According to the World Health Organization, cervical cancer is the most widespread form of pelvic cancer, with 570,000 women being diagnosed in 2018. In 2020, the number was 600,000, equivalent to 6.5 percent of female cancers. Cervical cancer is the most frequent cancer among women in over 30 lower and middle-income nations, with the majority in sub-Saharan Africa.

Thus, various therapeutic strategies are being developed to tackle the ever-growing issue. Of all the treatments treatment options, radiation therapy is most frequently used as a component of the treatment itself and also to manage its periodicity. The most frequently relied upon treatments are external beam radiation and brachytherapy.

External beam therapy uses radiation at the cancer site, however, with a greater dose of radiation. However, long-term exposure to these radiations increases the chance of developing lesions or ulcers in the pelvic region, particularly around the rectum. This leads to the development of proctitis around these areas, increasing the need for treatment in the most important areas.

What’s the reason? Hyperbaric Oxygen Therapy expected to open new possibilities?

Hyperbaric Oxygen Therapy (HBOT) is an additional treatment used to treat various diseases, including enteritis and radiation proctitis. In the course of treatment, patients can breathe 100% oxygen inside a chamber of treatment that is pressurized. The blood will be hyper oxygenated, promoting angiogenesis, collagen production, epithelialization, and improved leukocyte function.

HBOT is promoted as one of the only extremely effective treatments for patients suffering from severe radiation-induced symptoms such as cystitis and proctitis that cause bleeding. While the evidence available to date provides insufficient data about its efficacy, doctors are hopeful regarding its potential for future applications as clinical trials seek to establish concrete evidence.

The most recent HBOT trials have proven that healing reactions in patients suffering from refractory radio proctitis resulted in an overall risk decrease of 32%, with the need for other medical treatment requirements removed and the necessity for more advanced treatments largely eliminated.

Alternative non-oral Therapeutic Methods Increasing Growth Opportunities?

Apart from oral medication, notable companies and healthcare providers are offering a variety of alternatives to treatment, including laser treatments for remedial purposes to stop the continuous bleeding from the rectal. The administration of formaldehyde before surgery is also being looked at. In a clinical trial, the formalin dose of 4% was given to 20 patients with clinical and proctoscopic signs of radiation-induced proctitis.

The treatment was administered directly to the rectum with high-quality outcomes. The complete elimination of symptoms was seen in all patients. Furthermore, healthcare professionals perform the descending or transverse type of colostomy procedure for patients requiring surgery. The radiation proctitis treatment market is expanding the supply of intraperitoneal injections with formalin.

Other innovative methods like radiofrequency ablation and cold therapy (RFA) are gaining the interest of healthcare professionals. A colostomy is now a reliable and safe treatment for rectal ulcers of chronic proctitis patients. Colostomy can control bleeding from the rectal and relieves pain for patients.

Does the high cost of hyperbaric Oxygen Therapy stifle market growth?

Cost is among the main factors that affect the decision to choose a treatment. Oxygen therapy with hyperbaric is among the few options for patients suffering from severe radiation-induced symptoms. These include cystitis and proctitis, which causes bleeding.

The current state of hyperbaric oxygen therapy is costly, and consequently, people with low or middle incomes cannot pay for it, despite its significant benefits. This could be an obstacle to developing radiation therapy for the proctitis market.

Country-wise Analysis

Why is the demand for Radiation Proctitis Treatment High in the U.S.?

Based on the National Center for Biotechnology Information, The radiation therapy method is widely utilized to treat pelvic malignancies, including colorectal, prostate, and cervical cancer. Despite advances in radiation research, more than 75 percent of patients suffer from acute radiation proctitis, and up to 55% experience persistent symptoms.

There is a good chance that over 200 thousand patients undergo radiation therapy throughout the U.S. for abdominal, retroperitoneal, and pelvic cancers, such as but not only prostate, urinary, female, lymphoma, and rectal cancers. It is estimated that 1.5 two million patients suffer from radiation-induced intractable tract issues. Various gastrointestinal issues have been reported in more than 30% of cancer patients.

In the light of these developments, the potential for treating radiation proctitis throughout the country has grown dramatically. Manufacturers have a lot of opportunities in the field of hyperbaric oxygen treatment. Sechrist Industries Ltd. is a well-known manufacturer of this technology, providing products such as models 4100H, 3600H, 3300H, and 2800 pneumatic oxygen chambers. The future is bright for this technology can treat many cases of radiation proctitis, which could result in the development of numerous revenue streams.

What is the reason for Cervical Cancer Treatment Growing? U.K.s growth prospects?

It is believed that the U.K. radiation proctitis market is highly dependent on the increasing demand for treatment for cervical cancer. Based on Cancer Research U.K., between 2015 to 2017, every year, about 10% of all new cases (9 percent) were females over 75 years old. This is the 14th most frequent cancer for females and accounts for 2 percent of all cancer cases.

Through the years, massive technological advancements have brought advanced treatment methods, including radiotherapy. It accounts for 40% of total treatment for cancer in the U.K. Since it uses high-energy radiation to destroy cancerous cell lines, radiotherapy is recommended as a component of the treatment. But, this treatment comes with a variety of negative side effects.

The symptoms of diarrhea or vaginal bleeding, bladder inflammation as well as red and sore skin, and fatigue are all common. They are accompanied by other long-term effects like early menopausal changes, skin issues, and irritation to the rectum. Thus, the manufacturers are expected to expand their offerings in this area in the forecast for the long term.

Are Increasing Healthcare expenditures driving the Market in Germany? Market in Germany

According to the Economist Intelligence Unit, Germany has the highest healthcare expenditure of 11% or more of the European Union (E.U.). It is the second-highest in terms of per-capita expenditure. In 2019, the healthcare budget in Germany totaled 410.8 billion. This number increased by 19.3 billion in 2021 or 4.9 percent by 2021.

A large portion of this budget allocation has been devoted to supporting extensive cancer research and diagnosing methods. Most of these strategies employ conventional techniques, like chemotherapy, surgery or radiation therapy, targeted treatment, immunotherapy, and other advanced oncology methods to treat various cancers.

Unfortunately, the growing dependence on radiotherapy has led to an increase in the incidence of radiation-related proctitis. Thus, a variety of medications have been approved for treating ulcerative colitis, which is a typical manifestation that is caused by radiation. The most effective first-line treatment for moderate to mild ulcerative colitis comprises anti-inflammatory 5aminocsalicyclic acid (5-ASA) preparations that contain mesalazine, sulfasalazine, and.

Category-wise Insights

What is the role of chronic radiation Proctitis (CRP) treatment causing Market Expansion

Treatment for acute radiation-related proctitis has remained prevalent, attributed to the high prevalence rate (20 percent). Chronic treatment for proctitis caused by radiation is expected to grow significantly in the coming decade. Although acute side effects can manifest for up to three months following treatment, chronic side effects typically happen 3-6 months or even years post-radiation treatment.

The use of medical therapy that includes sucralfate and high amifostine has proved to be very efficient in providing an effective barrier to the immediate and long-term radiation-related effects. Furthermore, research has shown that synbiotics and macrobiotics may be utilized to alter intestinal flora and combat or treat CRP. Sun Pharmaceutical Industries is amongst the most prominent producers of amifostine drugs and drug candidates.

What is the reason why oral Therapy Radiotherapy Proctitis Therapy is Promised to remain the Most Popular?

Because of its low-risk nature, treatment with oral radiation proctitis therapy is anticipated to remain the dominant treatment. In the field of available oral treatments, anti-inflammatory medications are anticipated to be the most widely used. Balsalazide, mesalazine, and sulfa are among the most effective anti-inflammatory medications to treat radiation-related proctitis.

Several regional companies offer anti-inflammatory treatments. They include Valens Molecules (sulphasalazine), PharmaZell (balsalazide), Surya Life Sciences (mesalazine), Jiangsu RUIKE (sulphasalazine), Corden Pharma (sulphasalazine), and BEC Chemicals (mesalazine) to just some. These ingredients are extremely effective in eliminating oxygen radicals and inhibiting bacteria organisms.

The Competitive Landscape

The global radiation treatment market appears to be highly scattered, which is due to the existence of numerous local and global-level manufacturers. The primary expansion strategies are releasing new radiation treatment products, using collaborations and partnerships, scrambling for approvals from regulators, and acquiring competitors.

• In December of 2019, Amneal Pharmaceuticals Inc. signed a definitive contract that included the acquisition of the 65.1 percent stake of AvKARE and its affiliate that operates under the name R&S Northeast, valued at more than US$300 million. The acquisition of AvKARE will allow Amneal to diversify its operations in its entire U.S. federal healthcare market.
• In December 2020, Pfizer Inc. and Myovant Sciences announced a collaboration to develop and commercialize relugolix- a once-daily, gonadotrophin-releasing hormone (GnRH) receptor antagonist. The drug is expected to be released for women’s health and oncology throughout the U.S. and Canadian markets. The two companies will work together to create and market ORGOVYXTM to treat advanced prostate cancer and improve women’s health.
• In April 2021, Sanofi S.A. acquired Kiadis Pharma, an early-stage biopharmaceutical company developing next-generation off-the-shelf N.K. Cell therapies. This acquisition marks a new landmark in Sanofi’sSanofis’s growing presence in immuno-oncology. Sanofi is expected to hold about 95.03 percent of the outstanding capital shares in a fully diluted manner.

Report Scope